Clene stock increased by 9.4% to $0.47 during Wednesday's after-market session. The market value of their outstanding shares is at $60.7 million. • AcelRx…
In the world of investing, spotting stocks that are gaining momentum is a well-worn strategy for those seeking potential profits. These stocks, exhibiting remarkable movements, often sustain their.
What CEO Jason Okazaki called Assembly Biosciences Inc.’s “monumental” deal for new antivirals with Gilead Sciences Inc. brings $100 million right away, consisting of an $84.8 million up-front payment and a $15.2 million equity investment. Wall Street liked it, and shares of South San Francisco-based Assembly (NASDAQ:ASMB) closed Oct. 17 at $1.25, up 52 cents or 72%, on word of the 12-year arrangement. Gilead (NASDAQ:GILD) ended at $80.48, up $1.28.
Gilead Sciences (GILD) and Assembly Biosciences (ASMB) Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.